Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Increases By 61.2%

vTv Therapeutics Inc. (NASDAQ:VTVT) was the recipient of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 50,829 shares, a growth of 61.2% from the January 29th total of 31,525 shares. Based on an average trading volume of 28,349 shares, the days-to-cover ratio is currently 1.8 days. Approximately 1.3% of the shares of the stock are sold short. Approximately 1.3% of the shares of the stock are sold short. Based on an average trading volume of 28,349 shares, the days-to-cover ratio is currently 1.8 days.

Wall Street Analyst Weigh In

VTVT has been the topic of a number of research reports. BTIG Research reissued a “buy” rating and issued a $49.00 target price (up from $40.00) on shares of vTv Therapeutics in a research note on Tuesday, January 27th. Roth Mkm began coverage on vTv Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $58.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $47.00 target price (up from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. TD Cowen began coverage on vTv Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.25.

vTv Therapeutics Stock Down 3.0%

Shares of vTv Therapeutics stock opened at $38.16 on Monday. The firm has a market cap of $150.35 million, a PE ratio of -11.49 and a beta of 0.44. vTv Therapeutics has a 52 week low of $14.00 and a 52 week high of $44.00. The business’s fifty day simple moving average is $36.56 and its 200-day simple moving average is $28.21.

Institutional Investors Weigh In On vTv Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in VTVT. Goldman Sachs Group Inc. purchased a new position in shares of vTv Therapeutics during the 4th quarter worth approximately $221,000. 683 Capital Management LLC purchased a new stake in vTv Therapeutics in the fourth quarter valued at approximately $731,000. Geode Capital Management LLC lifted its stake in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP boosted its position in shares of vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after buying an additional 51,000 shares during the period. 17.51% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.